The Case For and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity

JACC: Cardiovascular Imaging

Volumn 9, Issue 8, 2016, Pages 994-1002

  McEvoy, John W ^a   Martin, Seth S ^a   Blaha, Michael J ^a   Polonsky, Tamar S ^b   Nasir, Khurram ^a,c,d   Kaul, Sanjay ^e   Greenland, Philip ^f   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c MIAMI CANCER INSTITUTE   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

coronary artery calcification; outcomes; randomized controlled trial

Indexed keywords

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIUM IMAGING; ECONOMIC ASPECT; HUMAN; LUNG CANCER; MEDICAL ETHICS; PATIENT SAFETY; PRIORITY JOURNAL; RADIATION DOSE REDUCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; STUDY DESIGN; BLOOD VESSEL CALCIFICATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; METHODOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR;

CLINICAL TRIALS AS TOPIC; COMPUTED TOMOGRAPHY ANGIOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 85008701918     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2016.03.012     Document Type: Review

References (49)

1. 1 Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
2. 2 Martin, S.S., Sperling, L.S., Blaha, M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 65 (2015), 1361–1368.
3. 3 McEvoy, J.W., Blaha, M.J., Coronary artery calcium testing: exploring the need for a randomized trial. Circ Cardiovasc Imaging 7 (2014), 578–580.
4. 4 McEvoy, J.W., Diamond, G.A., Detrano, R.C., et al. Risk and the physics of clinical prediction. Am J Cardiol 113 (2014), 1429–1435.
5. 5 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
6. 6 Pencina, M.J., Navar-Boggan, A.M., D'Agostino, R.B. Sr., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 370 (2014), 1422–1431.
7. 7 DeFilippis, A.P., Young, R., Carrubba, C.J., et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 162 (2015), 266–275.
8. 8 Cook, N.R., Ridker, P.M., Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med 174 (2014), 1964–1971.
9. 9 Ioannidis, J.P., More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 311 (2014), 463–464.
10. 10 Polonsky, T.S., McClelland, R.L., Jorgensen, N.W., et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 303 (2010), 1610–1616.
11. 11 Yeboah, J., McClelland, R.L., Polonsky, T.S., et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308 (2012), 788–795.
12. 12 Detrano, R., Guerci, A.D., Carr, J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358 (2008), 1336–1345.
13. 13 Erbel, R., Mohlenkamp, S., Moebus, S., et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 56 (2010), 1397–1406.
14. 14 Elias-Smale, S.E., Proenca, R.V., Koller, M.T., et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol 56 (2010), 1407–1414.
15. 15 Nasir, K., Bittencourt, M.S., Blaha, M.J., et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 66 (2015), 1657–1668.
16. 16 Pursnani, A., Massaro, J.M., D'Agostino, R.B. Sr., O'Donnell, C.J., Hoffmann, U., Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA 314 (2015), 134–141.
17. 17 Blaha, M.J., Budoff, M.J., DeFilippis, A.P., et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 378 (2011), 684–692.
18. 18 Miedema, M.D., Duprez, D.A., Misialek, J.R., et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes 7 (2014), 453–460.
19. 19 Shaw, L.J., Giambrone, A.E., Blaha, M.J., et al. Long-term prognosis after coronary artery calcification testing in asymptomatic patients: a cohort study. Ann Intern Med 163 (2015), 14–21.
20. 20 Rozanski, A., Gransar, H., Shaw, L.J., et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol 57 (2011), 1622–1632.
21. 21 Clinical Practice guidelines we can trust. Institute of Medicine. Available at: http://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx. Accessed July 10, 2015.
22. 22 Cholesterol Treatment Trialists, Mihaylova, B., Emberson, J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
23. 23 Anglemyer, A., Horvath, H.T., Bero, L., Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev, 4, 2014, MR000034.
24. 24 Shreibati, J.B., Baker, L.C., McConnell, M.V., Hlatky, M.A., Outcomes after coronary artery calcium and other cardiovascular biomarker testing among asymptomatic medicare beneficiaries. Circ Cardiovasc Imaging 7 (2014), 655–662.
25. 25 Khera, A., Texas atherosclerosis imaging bill: quiet origins, broad implications. Arch Intern Med 171 (2011), 281–283.
26. 26 Kim, K.P., Einstein, A.J., Berrington de Gonzalez A. Coronary artery calcification screening: estimated radiation dose and cancer risk. Arch Intern Med 169 (2009), 1188–1194.
27. 27 Horton, K.M., Post, W.S., Blumenthal, R.S., Fishman, E.K., Prevalence of significant noncardiac findings on electron-beam computed tomography coronary artery calcium screening examinations. Circulation 106 (2002), 532–534.
28. 28 Min, J.K., Lin, F.Y., Gidseg, D.S., et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the “warranty period” for remaining normal?. J Am Coll Cardiol 55 (2010), 1110–1117.
29. 29 Newman, C.B., Tobert, J.A., Statin intolerance: reconciling clinical trials and clinical experience. JAMA 313 (2015), 1011–1012.
30. 30 Fernandez, G., Spatz, E.S., Jablecki, C., Phillips, P.S., Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 78 (2011), 393–403.
31. 31 Sattar, N., Preiss, D., Murray, H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
32. 32 Fontana, M., Asaria, P., Moraldo, M., et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation 129 (2014), 2539–2546.
33. 33 McNulty, E.J., Hung, Y.Y., Almers, L.M., Go, A.S., Yeh, R.W., Population trends from 2000-2011 in nuclear myocardial perfusion imaging use. JAMA 311 (2014), 1248–1249.
34. 34 Vliegenthart, R., Morris, P.B., Computed tomography coronary artery calcium scoring: review of evidence base and cost-effectiveness in cardiovascular risk prediction. Journal of thoracic imaging 27 (2012), 296–303.
35. 35 van Kempen, B.J., Spronk, S., Koller, M.T., et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol 58 (2011), 1690–1701.
36. 36 Pletcher, M.J., Pignone, M., Earnshaw, S., et al. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 7 (2014), 276–284.
37. 37 Roberts, E.T., Horne, A., Martin, S.S., et al. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA). PloS One, 10, 2015, e0116377.
38. 38 Arad, Y., Spadaro, L.A., Roth, M., Newstein, D., Guerci, A.D., Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 46 (2005), 166–172.
39. 39 Ambrosius, W.T., Polonsky, T.S., Greenland, P., et al. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials 9 (2012), 232–246.
40. 40 Polonsky, T.S., Greenland, P., CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nat Rev Cardiol 9 (2012), 599–604.
41. 41 Kim, J., McEvoy, J.W., Nasir, K., et al. Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart trials. Circ Cardiovasc Qual Outcomes 7 (2014), 315–322.
42. 42 Nasir, K., Shaw, L.J., Budoff, M.J., Ridker, P.M., Pena, J.M., Coronary artery calcium scanning should be used for primary prevention: pros and cons. J Am Coll Cardiol Img 5 (2012), 111–118.
43. 43 Blaha, M., Budoff, M.J., Shaw, L.J., et al. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardiol Img 2 (2009), 692–700.
44. 44 Kopec, J.A., Abrahamowicz, M., Esdaile, J.M., Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 46 (1993), 959–971.
45. 45 National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
46. 46 McEvoy, J.W., Blaha, M.J., Rivera, J.J., et al. Mortality rates in smokers and nonsmokers in the presence or absence of coronary artery calcification. J Am Coll Cardiol Img 5 (2012), 1037–1045.
47. 47 Hecht, H.S., Henschke, C., Yankelevitz, D., Fuster, V., Narula, J., Combined detection of coronary artery disease and lung cancer. Eur Heart J 35 (2014), 2792–2796.
48. 48 Mets, O.M., de Jong, P.A., Prokop, M., Computed tomographic screening for lung cancer: an opportunity to evaluate other diseases. JAMA 308 (2012), 1433–1434.
49. 49 Chiles, C., Duan, F., Gladish, G.W., et al. Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods. Radiology 276 (2015), 82–90.